C0061355||glucagon-like peptide-1
C0020615||post-bariatric hypoglycaemia
C0020615||Post-bariatric hypoglycaemia
C0020615||Post-bariatric hypoglycaemia
C0025517||metabolic disorder
C1456587||bariatric surgery
C0020615||hypoglycaemia
C0021641||insulin
C1562292||incretin hormone
C3537152||signalling
C1256369||insulin secretion
C0020615||hypoglycaemia
C2603343||study
C0020615||Post-bariatric hypoglycaemia
C1457887||symptoms
C0061355||glucagon-like peptide-1
C0061355||glucagon-like peptide-1
C0013072||double-blinded
C0150097||crossover study
C0679646||participants
C0020615||Post-bariatric hypoglycaemia
C0021440||intravenous infusion
C0378073||GLP-1 receptor
C0378073||GLP-1 receptor
C0003139||antagonist
C0247947||Exendin (9-39)
C0247947||Ex-9
C0032042||placebo
C0029161||OGTT
C0041740||Stanford University
C1274109||Clinical and Translational Research Unit
C0599755||cohort
C1305855||BMI
C0017725||glucose
C0574032||Infusion
C0247947||Ex-9
C0017725||glucose
C0017725||glucose
C0029161||OGTT
C0020615||hypoglycaemia
C0020615||Post-bariatric hypoglycaemia
C0679646||participants
C0021641||Insulin
C0312431||secretion
C0021641||insulin
C2674101||Autonomic
C1457887||neuroglycopenic symptoms
C0247947||Ex-9
C0574032||infusion
C0378073||GLP-1 receptor
C0020615||hypoglycaemia
C0237401||individuals
C0007613||beta cell function
C1457887||reversed neuroglycopenic symptoms
C0061355||glucagon-like peptide-1
C1864903||hyperinsulinaemic hypoglycaemia
C0020615||Post-bariatric hypoglycaemia
C0013159||antagonism
C0378073||GLP-1 receptor